These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 11144908)

  • 1. Use of markers in defining urothelial premalignant and malignant conditions.
    Grossman HB; Schmitz-Dräger B; Fradet Y; Tribukait B
    Scand J Urol Nephrol Suppl; 2000; (205):94-104. PubMed ID: 11144908
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Current concepts of tumor markers in bladder cancer.
    Droller MJ
    Urol Clin North Am; 2002 Feb; 29(1):229-34. PubMed ID: 12109349
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genetic and molecular markers of urothelial premalignancy and malignancy.
    Cordon-Cardo C; Cote RJ; Sauter G
    Scand J Urol Nephrol Suppl; 2000; (205):82-93. PubMed ID: 11144907
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bladder cancer: natural history, tumor markers, and early detection strategies.
    Foresman WH; Messing EM
    Semin Surg Oncol; 1997; 13(5):299-306. PubMed ID: 9259085
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical use of urinary markers for the detection and prognosis of bladder carcinoma: a comparison of immunocytology with monoclonal antibodies against Lewis X and 486p3/12 with the BTA STAT and NMP22 tests.
    Friedrich MG; Hellstern A; Hautmann SH; Graefen M; Conrad S; Huland E; Huland H
    J Urol; 2002 Aug; 168(2):470-4. PubMed ID: 12131290
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prevention and treatment of urothelial premalignant and malignant lesions.
    Wijkström H; Cohen SM; Gardiner RA; Kakizoe T; Schoenberg M; Steineck G; Tobisu K
    Scand J Urol Nephrol Suppl; 2000; (205):116-35. PubMed ID: 11144892
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic comparison of proliferation markers and World Health Organization 1973/2004 grades in urothelial carcinomas of the urinary bladder.
    Mangrud OM; Gudlaugsson E; Skaland I; Tasdemir I; Dalen I; van Diermen B; Baak JP; Janssen EA
    Hum Pathol; 2014 Jul; 45(7):1496-503. PubMed ID: 24796506
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sensitivity and specificity of commonly available bladder tumor markers versus cytology: results of a comprehensive literature review and meta-analyses.
    Lotan Y; Roehrborn CG
    Urology; 2003 Jan; 61(1):109-18; discussion 118. PubMed ID: 12559279
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Cancerous and precancerous changes in the tumor margin areas of patients with bladder cancers].
    Blume B; Theuring F
    Z Urol Nephrol; 1985 Feb; 78(2):71-6. PubMed ID: 3993243
    [TBL] [Abstract][Full Text] [Related]  

  • 10. WHO 1973 grade 3 and infiltrative growth pattern proved, aberrant E-cadherin expression tends to be of predictive value for progression in a series of stage T1 high-grade bladder cancer after organ-sparing approach.
    Otto W; Breyer J; Herdegen S; Eder F; Bertz S; May M; Mayr R; Lausenmeyer EM; Denzinger S; van Rhijn BW; Burger M; Hartmann A
    Int Urol Nephrol; 2017 Mar; 49(3):431-437. PubMed ID: 28035618
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Multicolor FISH (UroVysion) facilitates follow-up of patients with high-grade urothelial carcinoma of the bladder.
    Fritsche HM; Burger M; Dietmaier W; Denzinger S; Bach E; Otto W; Doblinger M; Schwarz S; Buchner H; Hartmann A
    Am J Clin Pathol; 2010 Oct; 134(4):597-603. PubMed ID: 20855641
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Detection of residual tumor cells in bladder biopsy specimens: pitfalls in the interpretation of cytokeratin stains.
    Tamas EF; Epstein JI
    Am J Surg Pathol; 2007 Mar; 31(3):390-7. PubMed ID: 17325480
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [A study of dysplasia associated with bladder cancer--histopathological findings of bladder giant sections and related urinary cytology].
    Sekine H
    Nihon Hinyokika Gakkai Zasshi; 1989 Apr; 80(4):545-54. PubMed ID: 2747096
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hypocellular bladder wash specimens and their clinical significance.
    Kusuda L; Kimmel M; Fair WR; Melamed M
    J Urol; 1993 Oct; 150(4):1123-5. PubMed ID: 8371370
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical application of NMP22 in the management of transitional cell carcinoma of the bladder.
    Sawczuk IS; Bagiella E; Sawczuk AT; Yun EJ
    Cancer Detect Prev; 2000; 24(4):364-8. PubMed ID: 11059567
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Multiple mucosal biopsies and postoperative urinary cytology in patients with bladder cancer.
    Gil-Salom M; Sánchez MC; Chuan P; Clar F; Santamaría J; García-Sisamón F
    Eur Urol; 1990; 17(4):281-5. PubMed ID: 2364965
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Studies on multiple mucosal biopsy in patients with bladder cancer. 1. Evaluation of the results of multiple mucosal biopsy in patients with bladder cancer and in vivo methylene blue staining].
    Igawa M
    Hinyokika Kiyo; 1986 Nov; 32(11):1617-31. PubMed ID: 2435127
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cyclooxygenase-2 expression on urothelial and inflammatory cells of cystoscopic biopsies and urine cytology as a possible predictive marker for bladder carcinoma.
    Moussa M; Omran Z; Nosseir M; Lotfy A; Swellam T
    APMIS; 2009 Jan; 117(1):45-52. PubMed ID: 19161536
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Utility of ProEx C in the histologic evaluation of the neoplastic and nonneoplastic urothelial lesions.
    Moatamed NA; Vergara-Lluri ME; Lu D; Apple SK; Kerkoutian S; Rao JY
    Hum Pathol; 2013 Nov; 44(11):2509-17. PubMed ID: 24029711
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intraepithelial lesions of urinary bladder: morphologic considerations.
    Murphy WM; Busch C; Algaba F
    Scand J Urol Nephrol Suppl; 2000; (205):67-81. PubMed ID: 11144906
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.